Jeffrey Levenda, MD
Sports Medicine · Fort Wayne, INNPI 1619298411
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,751 of the $10,195 with a category attached, or 76.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,788 and has fallen 55.3% since, to $1,246 in 2025.
Across 459 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Crossroads Orthopedics, LLC$2K
- Novo Nordisk$2K
- Bayer$2K
- AbbVie$892
- AstraZeneca$837
- Lilly USA, LLC$792
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,75176%
- Education$2,44424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Crossroads Orthopedics, LLC | 1 | $2,400 |
| Novo Nordisk | 118 | $1,677 |
| Bayer | 91 | $1,574 |
| AbbVie | 54 | $892 |
| AstraZeneca | 41 | $837 |
| Lilly USA, LLC | 44 | $792 |
| Boehringer Ingelheim | 13 | $228 |
| Exact Sciences | 11 | $209 |
| Sanofi-aventis U.S. LLC | 11 | $203 |
| GSK | 11 | $195 |
| Abbott | 7 | $129 |
| Pfizer | 7 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $103 |
| Astellas Pharma US Inc | 5 | $99 |
| Novartis | 6 | $85 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Corcept Therapeutics | 2 | $58 |
| BD | 1 | $55 |
| Antares Pharma, Inc. | 2 | $47 |
| Bioventus LLC | 2 | $45 |
| Amgen | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Corium, LLC | 2 | $31 |
| Merck | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,195 in reported general payments places this provider in the 80th percentile of 156 sports medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 174 | $224,784 |
| MounjaroTirzepatide | 98 | $127,422 |
| EliquisApixaban | 79 | $68,541 |
| KerendiaFinerenone | 56 | $67,518 |
| FarxigaDapagliflozin Propanediol | 52 | $55,126 |
| JardianceEmpagliflozin | 41 | $43,925 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $39,705 |
| JanuviaSitagliptin Phosphate | 24 | $24,416 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $20,101 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $18,517 |
| TradjentaLinagliptin | 19 | $14,287 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $9,704 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,579 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,644 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,677 | $224,784174 claims |
| Lilly USA, LLCMounjaro | $792 | $127,42298 claims |
| PfizerEliquis, Dilantin | $114 | $69,66890 claims |
| BayerKerendia | $1,574 | $67,51856 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $837 | $66,78976 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $228 | $64,83572 claims |
| MerckJanuvia, Janumet Xr | $28 | $42,93344 claims |
| GSKBreo Ellipta | $195 | $9,57913 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,171296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 sports medicine providers in Indiana.
Other sports medicine in Fort Wayne
- Jason HannaFort Wayne$3K
- Stephen WrightFort Wayne$2K
- Jorge ChahlaMunster$917K
- Sean CallowayGreenwood$130K
- Ryan NixonGreenwood$62K
- Tyler McCarrollCarmel$60K
- Nedal AlkhatibIndianapolis$51K
- Stephen ShivelyGreenfield$51K
- Dale SneadCarmel$45K
- Gregory FoxBloomington$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.